Investor Presentaiton
Some of Eurofins' Innovations: Onconext - Next
Generation Oncology Diagnostics
* eurofins
• Onconext from Eurofins Genoma is an advanced molecular diagnostics solution for personalised
cancer care that uses state of the art technology
①
• The team comprises multidisciplinary professionals specialised in molecular biology and genetics NEXT RISK
applied to the study of cancer
Onconext includes an advanced suite of oncology panels:
• Onconext Risk: detects germline mutations involved in genetic predisposition to cancer
o Onconext Liquid: analysis of circulating tumor DNA (ctDNA) for cancer detection and
monitoring (liquid biopsy)
Next Generation Oncology Diagnostics
ONTO
。 Onconext Tissue: detects somatic mutations in tumor DNA (tDNA) from tissue samples coming NEXT
from traditional biopsies
and
• Those tests cover many of the most common cancer types including breast, ovarian/uterine,
melanoma, colon, gastric, pancreas, prostate, cerebral, renal,
pheocromocytoma/paraganglioma
•
Eurofins Genoma also develops tailor made solutions for its pharma customers and educate
oncologists in the clinical utility and use of Onconext in personalized medicine. The ultimate goal of
LIQUID
Next Generation Oncology Diagnostics
ONTO
those projects is to make liquid biopsy a reality for patients. An example of this kind of project is the NEXT
NGBreast project run in Italy with 80 oncology teams (see www.NGBreast.it)
TISSUE
Next Generation Oncology Diagnostics
14View entire presentation